Mitchell S. von Itzstein

Author

The University of Texas Southwestern Medical Center ORCID

Also Known As

Mitchell S von Itzstein, Mitchell S. Von Itzstein, Mitchell S. von Itzstein

Publications

580

Citations

H-Index

Concepts

All Affiliations

The University of Texas Southwestern Medical Center Southwestern Medical Center Johns Hopkins University

About

Mitchell S. von Itzstein is an author at The University of Texas Southwestern Medical Center specializing in medicine, lung cancer, and patient safety.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	28
2	Public Health	1	1	13
3	Allergy	1	1	15
4	Immunology	1	1	15
5	Pathology	1	1	15

Mitchell S. von Itzstein

Publications

287

Citations

H-Index

Page 1

	Year	Citations
Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors Murtaza Ahmed, Mitchell S. von Itzstein, Thomas Sheffield, Journal for ImmunoTherapy of Cancer	2021	39
Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors Mitchell S. von Itzstein, Amrit S. Gonugunta, Yiqing Wang, Cancer Immunology Immunotherapy	2022	30
Use of artificial intelligence chatbots in clinical management of immune-related adverse events Hannah Burnette, Aliyah Pabani, Mitchell S. von Itzstein, Journal for ImmunoTherapy of Cancer	2024	29
Late-Onset Immunotherapy Toxicity and Delayed Autoantibody Changes: Checkpoint Inhibitor–Induced Raynaud's-Like Phenomenon Shaheen Khan, Mitchell S. von Itzstein, Rong Lü, The Oncologist	2020	23
Type and case volume of health care facility influences survival and surgery selection in cases with early‐stage non–small cell lung cancer Shidan Wang, Sunny Lai, Mitchell S. von Itzstein, Cancer	2019	22
Association between Antibiotic Exposure and Systemic Immune Parameters in Cancer Patients Receiving Checkpoint Inhibitor Therapy Mitchell S. von Itzstein, Amrit S. Gonugunta, Thomas Sheffield, Cancers	2022	21
Statin Intolerance, Anti-HMGCR Antibodies, and Immune Checkpoint Inhibitor-Associated Myositis: A “Two-Hit” Autoimmune Toxicity or Clinical Predisposition? Mitchell S. von Itzstein, Shaheen Khan, Vinita Popat, The Oncologist Heart FailureStatin IntoleranceImmunodeficienciesImmunologyPathology	2020	15
Closing the gap: Contribution of surgical best practices to outcome differences between high‐ and low‐volume centers for lung cancer resection Mitchell S. von Itzstein, Rong Lü, Kemp H. Kernstine, Cancer Medicine	2020	14
Increasing Numbers and Reported Adverse Events in Patients with Lung Cancer Undergoing Inpatient Lung Biopsies: A Population-Based Analysis Mitchell S. von Itzstein, Arjun Gupta, Kristin C. Mara, Lung Adverse EventsCancer EpidemiologyAdvanced Lung DiseaseMedicineEpidemiology Of Cancer	2019	13
Patient familiarity with, understanding of, and preferences for clinical trial endpoints and terminology Mitchell S. von Itzstein, Elda Railey, Mary Lou Smith, Cancer	2020	13

Page 1